Two products, each aimed at one specific readout in preclinical drug development. Below is exactly what they do, the studies they belong in, and the conditions under which they pay off.
Brightfield images go in. EasyStain predicts the tau signal an antibody stain would have revealed, quantifies it for every cell, and compares treated cells against untreated controls to measure how far a candidate moves the pathology.
Trajectories that keep hold of a cell across long acquisitions, at the horizon the biological question is actually posed on.
Ordinary brightfield images go in. Every cell comes back with a predicted tau level: the same per-cell readout an antibody stain would have given you, with the plate left intact.
Tau located and quantified cell by cell across the whole population, so a well becomes a distribution of per-cell values rather than one plate-level average.
Compare the tau distribution in treated cells against untreated controls and quantify how far a candidate moves it. This is the number the assay exists to produce.
The readout leaves the cells alive, so the same plate can be re-imaged at every timepoint. A six-timepoint design running six plates per timepoint needs 36 plates under staining, and six here.
The input is ordinary brightfield from any microscope, so plates you have already imaged can be run through the same readout.
A fast, non-destructive first pass. Antibody panels stay in the workflow for isoform-level and multiplexed confirmation.
Cells elongate and change shape, they occlude one another and their targets, and the statistics of their motion shift with functional state, between scanning and attack. Each of these breaks a trajectory, and every event defined at the level of the individual cell is lost with it.
A T cell may kill several cancer cells in succession, hopping between them. The behaviour becomes observable once identity survives the hops.
A T cell attacks an organoid and kills it. The organoid occludes the cell during the attack, which is exactly where a trajectory tends to break and where the kill goes unrecorded.
A newer and increasingly relevant readout, and one that resolves only over long observation with identity preserved throughout.
Comparing how T cells behave under different constructs or doses across the full length of the acquisition.
Advancing a compound requires specific evidence. Long-horizon readouts that hold up let treatment validity be tested at the horizon the claim is actually made about.
The manual merge, split and stitch tool doubles as a way to build annotated trajectory sets for your own benchmarking.
Plate and culture costs compound across many paying clients. Removing the staining step and enabling longitudinal single-plate imaging improves margin and allows more competitive quotes.
Fewer campaigns, but acute sensitivity to cycle time and cash burn, and decision cycles short enough that a single pilot can be authorised directly. Our natural early adopters and design partners.
Longer procurement cycles, and multi-site, multi-user deployments in return. The tau field alone supports a substantial number of active programmes.
We would be glad to walk you through either tool on your own images and discuss how it fits your pipeline.
Talk to us